Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.72Last Year’s EPS
0.2Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 14.05%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
Harmony Biosciences demonstrated strong financial and operational performance with significant growth in WAKIX sales and a robust pipeline, despite facing some seasonal and expense-related challenges.Company Guidance
During Harmony Biosciences' first quarter 2025 financial results call, several key metrics and guidance were provided. The company reported a net product revenue of $184.7 million for the quarter, marking a 20% year-over-year increase. Harmony reaffirmed its net revenue guidance for the full year 2025, projecting between $820 million and $860 million, with expectations to surpass $1 billion in narcolepsy alone. The business remains profitable, with a non-GAAP adjusted net income of $60.4 million, up 19% from last year. The company holds over $600 million in cash and investments, supporting its robust pipeline, including eight assets across 13 development programs. Harmony is particularly focused on advancing its late-stage pipeline, with six programs expected to be in Phase 3 trials by year-end. A pivotal milestone anticipated in the third quarter is the top-line data readout from the Phase 3 RECONNECT study of ZYN002 in Fragile X Syndrome, which could significantly impact the company's trajectory.Strong Growth in WAKIX Sales
Net product revenue for the quarter was $184.7 million, representing a 20% increase year-over-year, reflecting strong demand and market penetration.
Robust Pipeline Development
Harmony Biosciences has 8 assets across 13 development programs, with plans to have up to 6 programs in Phase 3 trials by the end of the year, indicating a strong late-stage pipeline.
Financial Strength and Profitability
Harmony ended the first quarter with $610.2 million in cash, cash equivalents, and investments, and reported non-GAAP adjusted net income of $60.4 million, a 19% increase from the prior year.
Strategic Initiatives for Future Growth
Plans to initiate Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in Q4 2025, with potential peak sales of $1 billion to $2 billion per franchise.
HRMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HRMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $29.96 | $32.05 | +6.98% |
Feb 25, 2025 | $34.18 | $36.97 | +8.16% |
Oct 29, 2024 | $35.75 | $41.49 | +16.06% |
Aug 06, 2024 | $30.92 | $32.83 | +6.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Harmony Biosciences Holdings (HRMY) report earnings?
Harmony Biosciences Holdings (HRMY) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Harmony Biosciences Holdings (HRMY) earnings time?
Harmony Biosciences Holdings (HRMY) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HRMY EPS forecast?
HRMY EPS forecast for the fiscal quarter 2025 (Q2) is 0.72.